ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.
24/01/12
Directors Dealings08/11/11
Notification of Major Interest in Shares03/11/11
LupuzorT granted approval to start phase III01/11/11
Notification of Major Interest in Shares01/11/11
Notification of Major Interest in Shares
03/02/12
We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.
21/11/11
Merchant Securities today initiated coverage of ImmuPharma with a ‘buy’ recommendation and 323 pence share price target. The valuation is based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.
15/11/11
Investment Bank Espirito Santo has given a bullish assessment of the prospects for ImmuPharma and its lead drug Lupuzor as it has come up with a 200 pence valuation for the shares.
03/11/11
ImmuPharma chief executive Dimitri Dimitriou said he is very “optimistic about the future” as the company looks to seal a new licensing deal for Lupuzor, its flagship product. He revealed the group had “rekindled discussions” with big pharmaceuticals companies, and he is hopeful a deal can be struck.
03/11/11
Any lingering doubts over Immupharma’s lead drug, Lupuzor, were dispelled this morning when the group announced it would enter phase III clinical trials.
24/01/12
ImmuPharma: Two directors increase holdings in firm21/10/11
ImmuPharma regains rights to Lupuzor drug after Teva/Cephalon deal11/10/11
Teva's takeover of Cephalon may enable ImmuPharma to relicence Lupuzor, says Edison30/09/11
ImmuPharma to update on Lupuzor trials once Cephalon's takeover is completed02/08/11
ImmuPharma's future partner Teva may focus on Lupuzor after its failed MS trial, says Panmure
11/05/2010
15/10/2009
ImmuPharma is a drug discovery and development company focused on developing novel medicines to treat serious medical conditions and address a high unmet need with low marketing costs and a relatively low risk of drug development failure.
It is developing five drug candidates with significant sales potential to treat:
• Lupus (Systemic Lupus Erythematosus)
• Cancer
• Moderate to severe cancer or post-operative pain
• Highly resistant, hospital-acquired infections, such as MRSA
• Inflammatory and allergic disorders
ImmuPharma has a significant collaborative research and development agreement with the Centre National de la Recherche Scientifique, France’s scientific research institution (http://www.cnrs.fr/index.html). The agreement grants ImmuPharma worldwide exclusive rights to exploit commercially certain discoveries relating to the therapeutic use of peptides and peptide discoveries.
Alongside these collaborations, the company is using innovative technologies to develop a strong proprietary pipeline and patent portfolio of potential new drugs. ImmuPharma plans either to bring its discoveries to market itself or license them to other pharmaceutical companies.
ImmuPharma was first founded in Basel, Switzerland in 1999.
ImmuPharma has five lead drug candidates in development, each of which targets a niche market and addresses a serious medical condition. Each of them also has potentially significant sales, lower entry marketing costs and a relatively low risk of drug development failure.
Treatment for Lupus (Lupuzor TM)
Lupus is a chronic, potentially life-threatening autoimmune disease. An estimated one million people in the seven major markets have been diagnosed with this inflammatory disease which attacks multiple organs such as the skin, joints, kidneys, blood cells, heart and lungs. There is currently no cure or specific treatment. Lupuzor™ has a novel mechanism of action aimed at modulating the body’s immune system so it does not attack healthy cells without causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
ImmuPharma entered into a corporate deal with Cephalon Inc in November 2008 whereby Cephalon licensed worldwide the exclusive rights to Lupuzor™. Cephalon is now responsible for the development and commercialisation of Lupuzor™.
Treatment for cancer (IPP-204106)
IPP-204106, has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. IPP-204106 is a nucleolin antagonist, the lead molecule in a family of pseudopeptides designed to block the activity of a protein called nucleolin. Located essentially in the nucleus of normal cells where it is protected, nucleolin is much more abundant (often 30 times more) at the surface of the cells which are proliferating as well as the surface of active endothelial cells where it can be a target for antagonist peptides.
Relief from severe cancer and post-operative pain (IPP-102199)
ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year.
Treatment for highly resistant, hospital-acquired infections, such as MRSA (IPP-203101)
This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant.
Treatment for inflammatory and allergic disorders (IPP-201007)
Discovered from ImmuPharma's library of compounds, this is a Phospholipase A2 (PLA2) inhibitor chemical series with the potential to reduce allergic reactions and inflammatory conditions.
Management and Scientific Team
ImmuPharma's management team has over 100 years combined experience in the international pharma industry. It includes experienced executives and prominent scientists who provide expertise and contacts in the industry and the financial markets.
Richard Warr MA - Chairman
Richard Warr has 20 years’ experience in investment banking and corporate and government equity capital market transactions and was the architect of a large AIM flotation in 2004. Prior to co-founding ImmuPharma, he held positions as a director at ABN Amro Equities, head of European sales and marketing at Credit Lyonnais, executive director of Dresdner Kleinwort Benson and head of European equity distribution at Swiss Bank Corporation. He is a graduate of Oxford University.
Dimitri F Dimitriou MSc - Chief Executive Officer
Dimitri Dimitriou has over 20 years’ experience in the pharmaceutical and biotech industry. His past roles include senior director, worldwide business development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He spend 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career at Novartis (Sandoz) in 1987. He is the founder and chief executive officer of DyoDelta Biosciences, a company specialising in transactions between pharma and biotech companies. He has a degree in biochemistry from Chelsea College (now Kings College, London) and an MSc in pathology and toxicology from the Royal Postgraduate Medical School (now Imperial College Medical School).
Dr Robert Zimmer MD, PhD - President and Chief Scientific Officer
Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.
Tracy Weimar BA, MBA - Vice President, Operations & Finance
Ms Weimar has spent over 8 years at GlaxoSmithKline and her most recent position was Director, Worldwide Business Development where she was involved in a number of corporate licensing deals. She has also held a number of positions in health economics, strategy development, sales and marketing.
Since 2004, Ms Weimar has been a non-executive director for the Avon and Wiltshire Mental Health Partnership NHS Trust responsible for ensuring the Trust is accountable to the public for the services it provides and for the public funds it uses. She is a member of both the Audit and Remuneration Committees of the Trust.
Prior to joining GlaxoSmithKline, Ms Weimar spent 5 years at Arthur Andersen in San Francisco and London, responsible for a range of consulting and compliance projects.
Ms Weimar holds an MBA from the London Business School and a BA in Economics from the University of California, Berkeley.
Dr Franco Di Muzio - Non-Executive Director
Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000.
Dr Ajay Agrawal, PhD - Non-Executive Director
Dr Agrawal has almost 20 years’ experience in the biotech and pharmaceutical industry worldwide. He was a founder of polyMASC Pharmaceuticals plc, London in 1995, the first UK biotech company, derived from a university that was directly listed on AIM, raising approximately $40 million in 1995, and subsequently merged with a NASDAQ-listed company, Valentis Inc (USA) in 1999 to become one of the biggest companies in the delivery of biologics at that time. He currently sits on the editorial advisory board of three international medical journals, Current Drug Delivery, Infectious Disorders- Drug Targets, and Recent Patents on Drug Delivery and Formulation, Bentham Press, California, USA. Dr Agrawal has been a consultant to a number of companies in the sector, including Genovac GmbH (Germany), Qiagen (Germany), PHT Pharma (Italy) and Karo Bio (Sweden). He holds a PhD in Chemistry and has conducted his post-doctoral research in the faculty of Medicine, University of Alberta, Canada and at the Royal Free Hospital in London
Dr Paolo Bessieres - Vice President, Business Development
Dr. Paolo Bessieres has been involved in numerous collaboration projects over the past 20 years and has finalised over 20 deals. His experience includes partnerships for products and the creation of joint ventures and overseeing the alliance management. Dr Bessieres is also the CEO of PharmaWave Ltd, a company specialising in corporate partnerships in the life sciences. Prior to this, Dr Bessieres was Licensing Director at Sigma Tau, the second largest Italian pharmaceutical company. Dr Bessieres received his honours degree in Pharmacy in 1973 at the University of Rome, has been a member of many professional organisations as well as a speaker in international conferences.
Paddy Walker-Taylor - Financial Advisor
Paddy Walker-Taylor was finance director of Newarthill, the holding company of Sir Robert McAlpine, the privately-owned UK construction and property group. He was involved in the AIM float of ISG Group in which McAlpine had a minority stake. Previously he spent 20 years in the retail sector initially as treasury executive at Marks & Spencer in the UK and then vice president finance of its US operation. He became finance director of Woolworths and subsequently director of financial control at Kingfisher, Woolworth’s parent company. Since taking early retirement, he has been providing finance director services to small and medium-sized companies.
Key manager
Dr Jean-Marie Geiger, PharmD, MD Head of Clinical Development
Key scientists
Dr Jean-Gérard Guillet, PhD co-founder of ImmuPharma France
Dr Sylviane Muller, PhD co-founder of ImmuPharma France
Dr Gilles Guichard, PhD co-founder of ImmuPharma France
Dr Jean-Paul Briand, PhD co-founder of ImmuPharma France
Registered Office
50 Broadway, London SW1H 0BL, UK
Registrars
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK
Nominated Advisor & Broker
Panmure Gordon & Co. plc, 155 Moorgate, London EC2M 6XB, UK. Andrew Burnett Tel +44 151 243 0963, Rakesh Sharma +44 20 7459 3600
Joint Broker
Execution Noble, The Old Truman Brewery, 91 Brick Lane, London E1 6QL, UK. James Bromhead Tel + 44 20 7456 9191
Public Relations
Buchanan Communications, 6th Floor, 45 Moorfields, London EC2Y 9AE, UK. Lisa Baderoon, Director, Tel: +44 20 7466 5000
Auditors
Nexia Audit Limited, 25 Moorgate, London EC2R 6AY, UK
Administration and Investor Relations
ImmuPharma plc
50 Broadway
Westminster
London SW1H 0RG
UK
Tel: +44 20 7152 4080
Fax: +44 20 7152 4001
info@immupharma.com
R&D and Operations
ImmuPharma France SA
Technopôle 40
Rue Marc Seguin
68100 Mulhouse
France
Tel: + 33 389 32 76 50
Fax: + 33 389 32 76 31
ImmuPharma has 81,091,463 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings. The company does not hold any Ordinary Shares in treasury. The Company is not aware of any interest of 2% or more in the share capital of the Company other than the persons noted below. Number of Ordinary 10p shares % of issued share capital Dr Robert Zimmer 23,056,602 28% As far as the Company is aware, the percentage of the Company's issued share capital that is not in public hands is 37%. This percentage comprises the holdings of Directors.
M&G Investments
Dimitri Dimitriou
Richard Warr
Pictet % Cie
ING Investment Management
Aviva Investors Global
Odey Asset Management
7,600,000
3,528,968
3,528,968
3,287,500
3,245,280
1,748,363
1,628,465
9%
4%
4%
4%
4%
2%
2%
Copyright © Proactiveinvestors.co.uk, 2010. All Rights Reserved Design & Development: Tehnicom Computers
